Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.53 |
| ▸ | WNT3A | P56704 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601127 | 1.00 | CES2 (0.59) | CES2CES1L3MBTL1GRM4LMNA | |
| Bromide SCHEMBL29601697 | 0.98 | CES2 (0.57) | CES2CES1L3MBTL1GRM4LMNA | |
| Hydrochloric Acid SCHEMBL6833226 | 0.98 | CES2 (0.57) | CES2CES1L3MBTL1GRM4LMNA | |
| Bromide SCHEMBL1016601 | 0.98 | CES2 (0.57) | CES2CES1L3MBTL1GRM4LMNA | |
| Bromide SCHEMBL5121089 | 0.96 | CES2 (0.55) | CES2CES1L3MBTL1GRM4LMNA | |
| Pyridine SCHEMBL8599632 | 0.93 | L3MBTL1 (0.55) | CES2CES1L3MBTL1GRM4LMNA | |
| SCHEMBL12777709 | 0.83 | CES2 (0.59) | CES2CES1L3MBTL1GRM4LMNA | |
| SCHEMBL2470002 | 0.83 | CTNNB1 (0.71) | CES2CES1L3MBTL1GRM4LMNA | |
| SCHEMBL253276 | 0.83 | CES2 (0.64) | CES2CES1L3MBTL1GRM4LMNA | |
| SCHEMBL29355245 | 0.83 | CES2 (0.64) | CES2CES1L3MBTL1GRM4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 533 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58110505-A | — | — | None | — | — | JP | disclosed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| EP-4626896-A1 | POLYELECTROPHILIC METALATED HETEROCYCLES DERIVED FROM 2-(PYRIDIN-2-YL)IMIDAZO[1,2-A]PYRIDINE AND USE THEREOF AS CHEMOTHERAPEUTIC AGENTS | Universidad del País Vasco/Euskal Herriko Unibertsitatea (ES) | 2025-10-08 | — | — | EP | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025015429-A1 | IMIDAZOPYRIMIDINE-BASED MULTIMETALLIC CATALYSTS | SCHIPPER DEREK JAMES (CA) | 2025-01-23 | — | — | WO | disclosed |
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-118176185-A | 2- (Aryl-2-yl) morpholine and deuterated derivative thereof, preparation method and application | 上海翰森生物医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024115550-A1 | POLYELECTROPHILIC METALATED HETEROCYCLES DERIVED FROM 2-(PYRIDIN-2-YL)IMIDAZO[1,2-A]PYRIDINE AND USE THEREOF AS CHEMOTHERAPEUTIC AGENTS | UNIVERSIDAD DEL PAÍS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2024-06-06 | — | — | WO | disclosed |
| EP-4355426-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-04-24 | — | — | EP | disclosed |
| US-20240109914-A1 | IMIDAZOTHIAZOLE COMPOUNDS AND ANALOGS THEREOF AND METHODS FOR TREATING NEMATODE INFECTIONS IN PLANTS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2024-04-04 | — | — | US | disclosed |
| EP-0306300-A2 | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-03-08 | — | — | EP | disclosed |
| US-4692525-A | HYPOTENSIVE AGENTS, ESTERIFICATION | MALESCI S.P.A. ISTITUTO FARMACOBIOLOGICO (IT) | 1987-09-08 | — | — | US | disclosed |
| EP-0190900-A2 | Cephalosporin compounds, their production, and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-08-13 | — | — | EP | disclosed |
| US-4578467-A | Process for the preparation of 1-pyridyl-alkyl-4-aryl piperazines which are useful as antihypertensive compounds, their separation into the respective optical antipodes, and the stereoisomeric compounds so obtained | MALESCI S.P.A. INSTITUTO FARMACOBIOLOGICO (IT) | 1986-03-25 | — | — | US | disclosed |
| EP-0129409-A2 | Thiazolo - and thiazinobenzimidazoles | JOHN WYETH & BROTHER LIMITED (GB) | 1984-12-27 | — | — | EP | disclosed |
| EP-0092459-A2 | Imidazo(1,2-a)pyridines, their preparation and therapeutical use | SYNTHELABO (FR) | 1983-10-26 | — | — | EP | disclosed |
| JP-S58110505-A | GERMICIDE | ISHIHARA SANGYO KAISHA LTD | 1983-07-01 | — | — | JP | disclosed |
| EP-0072743-A1 | 1,2-Dithiol-3-ylidene ammonium derivatives, process for their preparation and medicines containing them | RHONE-POULENC SANTE (FR) | 1983-02-23 | — | — | EP | disclosed |
| US-4254267-A | HYPOTENSIVE ACTIVITY | E. R. SQUIBB & SONS, INC. (US) | 1981-03-03 | — | — | US | disclosed |
| US-4005212-A | ANTIDEPRESSANT, ANOREXIGENIC, PSYCHOENERGIZING, 2-PHENYL-2,3,5,6-TETRAHYDROIMIDAZO(2,1-B)THIAZOLE | RHONE-POULENC S.A. (FR) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109914-A1 | IMIDAZOTHIAZOLE COMPOUNDS AND ANALOGS THEREOF AND METHODS FOR TREATING NEMATODE INFECTIONS IN PLANTS | NISCH, ABAT, ICMT | CES2 2538/4885CES1 1880/4885L3MBTL1 687/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | CES2 1314/4885CES1 108/4885L3MBTL1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.